Silence Therapeutics Statistics
Total Valuation
Silence Therapeutics has a market cap or net worth of 247.41 million. The enterprise value is 74.71 million.
| Market Cap | 247.41M |
| Enterprise Value | 74.71M |
Important Dates
The next estimated earnings date is Thursday, March 13, 2025.
| Earnings Date | Mar 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +21.51% |
| Shares Change (QoQ) | +0.71% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 25.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.95 |
| EV / Sales | 3.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.27 |
Financial Position
The company has a current ratio of 9.31, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.31 |
| Quick Ratio | 8.61 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -102.80% and return on invested capital (ROIC) is -63.40%.
| Return on Equity (ROE) | -102.80% |
| Return on Assets (ROA) | -27.27% |
| Return on Invested Capital (ROIC) | -63.40% |
| Return on Capital Employed (ROCE) | -38.25% |
| Revenue Per Employee | 199,754 |
| Profits Per Employee | -723,788 |
| Employee Count | 109 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.67% in the last 52 weeks. The beta is 1.29, so Silence Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -32.67% |
| 50-Day Moving Average | 2.59 |
| 200-Day Moving Average | 5.74 |
| Relative Strength Index (RSI) | 47.49 |
| Average Volume (20 Days) | 429 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.05 |
Income Statement
In the last 12 months, Silence Therapeutics had revenue of 21.77 million and -78.89 million in losses. Loss per share was -1.79.
| Revenue | 21.77M |
| Gross Profit | 9.75M |
| Operating Income | -78.16M |
| Pretax Income | -88.37M |
| Net Income | -78.89M |
| EBITDA | -77.75M |
| EBIT | -78.16M |
| Loss Per Share | -1.79 |
Balance Sheet
The company has 172.89 million in cash and 186,302 in debt, giving a net cash position of 172.70 million.
| Cash & Cash Equivalents | 172.89M |
| Total Debt | 186,302 |
| Net Cash | 172.70M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 126.68M |
| Book Value Per Share | 2.68 |
| Working Capital | 188.45M |
Cash Flow
In the last 12 months, operating cash flow was -58.75 million and capital expenditures -156,815, giving a free cash flow of -58.90 million.
| Operating Cash Flow | -58.75M |
| Capital Expenditures | -156,815 |
| Free Cash Flow | -58.90M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 44.78% |
| Operating Margin | -358.97% |
| Pretax Margin | -405.85% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Silence Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.51% |
| Shareholder Yield | -21.51% |
| Earnings Yield | -31.89% |
| FCF Yield | -23.81% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Silence Therapeutics has an Altman Z-Score of 2.07. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.07 |
| Piotroski F-Score | n/a |